These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25763727)

  • 21. Molecular imaging of cell-mediated cancer immunotherapy.
    Lucignani G; Ottobrini L; Martelli C; Rescigno M; Clerici M
    Trends Biotechnol; 2006 Sep; 24(9):410-8. PubMed ID: 16870284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
    Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
    J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations.
    Aptsiauri N; Carretero R; Garcia-Lora A; Real LM; Cabrera T; Garrido F
    Cancer Immunol Immunother; 2008 Nov; 57(11):1727-33. PubMed ID: 18491093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiological evaluation of the therapeutic response of malignant diseases: status quo, innovative developments and requirements for radiology.
    Höink AJ; Heindel W; Buerke B
    Rofo; 2014 Oct; 186(10):927-36. PubMed ID: 25122173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
    Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
    Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma.
    Straatsma BR; Nusinowitz S; Young TA; Gordon LK; Chun MW; Rosen C; Seja E; Economou JS; Glaspy JA; Bozon V; Gomez-Navarro J; Ribas A
    Am J Ophthalmol; 2007 Jun; 143(6):958-969. PubMed ID: 17434437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cancer immunotherapy].
    Hurtado Ruano T
    Rev Esp Oncol; 1984; 31(2):359-69. PubMed ID: 6545712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Pictorial Essay of Immunotherapy: Complications that Internists Will See, Whether They Like it or Not.
    Evens A; Cyriac G; Jeong D; Araujo C; Gage K; Rose T
    Am J Med; 2019 Jul; 132(7):808-815. PubMed ID: 30849381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primer on immuno-oncology and immune response.
    Kannan R; Madden K; Andrews S
    Clin J Oncol Nurs; 2014 Jun; 18(3):311-7, 326. PubMed ID: 24867111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1 and 1.0.
    Chalian H; Töre HG; Horowitz JM; Salem R; Miller FH; Yaghmai V
    Radiographics; 2011; 31(7):2093-105. PubMed ID: 22084190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges.
    Teng F; Kong L; Meng X; Yang J; Yu J
    Cancer Lett; 2015 Aug; 365(1):23-9. PubMed ID: 25980820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response criteria in oncologic imaging: review of traditional and new criteria.
    Tirkes T; Hollar MA; Tann M; Kohli MD; Akisik F; Sandrasegaran K
    Radiographics; 2013; 33(5):1323-41. PubMed ID: 24025927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Problems and prospects of new immunotherapeutic approaches.
    Fridman WH; Mathiot C; Michon J; Teillaud JL; Dorval T; Zucker JM; Pouillart P
    Cancer Detect Prev; 1990; 14(6):657-60. PubMed ID: 2257565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting innate immune pathways in cancer immunotherapy: state of the art.
    Mastellos DC
    J BUON; 2009 Sep; 14 Suppl 1():S123-30. PubMed ID: 19785054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiological assessment of response and adverse events associated with novel systemic oncological therapies.
    Veerasuri S; Little D; De Paepe KN; Andreou A; Bowen R; Beresford M; Tillett T; Gangadhara S; Loughborough WW
    Clin Radiol; 2021 Apr; 76(4):247-261. PubMed ID: 33423761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy.
    Wojtowicz-Praga S
    J Immunother; 1997 May; 20(3):165-77. PubMed ID: 9181454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Manage immune-related adverse events associated with cancer immunotherapies.
    Becze E
    ONS Connect; 2014 Sep; 29(3):36-7. PubMed ID: 25223202
    [No Abstract]   [Full Text] [Related]  

  • 39. Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatment.
    Maffezzini M; Simonato A; Fortis C
    Prostate; 1996 May; 28(5):282-6. PubMed ID: 8610053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular imaging to select cancer therapy and evaluate treatment response.
    Mankoff DA
    Q J Nucl Med Mol Imaging; 2009 Apr; 53(2):181-92. PubMed ID: 19293766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.